Cecile H. Herbreteau

Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.

Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.

Journal: The Journal of infectious diseases

Published: April 16, 2022

In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab')2.

In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab')2.

Journal: The Journal of infectious diseases

Published: September 26, 2018

Past, present and future therapeutic and prophylactic strategies against arenaviruses responsible of human hemorrhagic fever.

Past, present and future therapeutic and prophylactic strategies against arenaviruses responsible of human hemorrhagic fever.

Journal: Virologie (Montrouge, France)

Published: December 01, 2017

Description and characterization of a novel live-attenuated tri-segmented Machupo virus in Guinea pigs.

Description and characterization of a novel live-attenuated tri-segmented Machupo virus in Guinea pigs.

Journal: Virology journal

Published: November 16, 2017

Mammarenaviruses deleted from their Z gene are replicative and produce an infectious progeny in BHK-21 cells.

Mammarenaviruses deleted from their Z gene are replicative and produce an infectious progeny in BHK-21 cells.

Journal: Virology

Published: September 22, 2017

Efficacy of a specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir.

Efficacy of a specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir.

Journal: Immunotherapy

Published: July 06, 2016

Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study.

Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study.

Journal: The Lancet. Infectious diseases

Published: February 10, 2015

Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice.

Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice.

Journal: Immunotherapy

Published: March 29, 2014

Showing 1-8 of 8

Last Updated: 09/26/2026